News

2018 Mid-Year Update from WGND

As the global TB drug development community pushes forward to find new drug candidates and develop novel regimens to combat the TB epidemic, we'd like to highlight some updates in the field, WGND activities, and upcoming events in 2018. 

Upcoming Events in 2018: 

  • UN General Assembly holding high-level meeting on TB to take place 26 September 2018
  • 2018 WGND Annual Meeting is being planned to occur the week of October 23rd in The Hague, Netherlands. Further details will be disseminated soon.
More News
9 Jul 2020
Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the...
18 Jun 2020
On May 21st, Antimicrbial Agents and Chemotherapy published an article on Otsuka's novel anti-tuberculosis compound, OPC-167832. This molecule, a DprE1 inhibitor, demonstrated potent bactericidal activity and exhibited significant combination effects in 2-drug combinations with delamanid,...
17 Jun 2020
On March 25th, Qurient announced the results of their Phase 2 Clinical Trial (ClinicalTrials.gov number, NCT03563599 ), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed...